Evidence map›Paper›PMID 37528323›Full record

ArticleHandbook of experimental pharmacology2024

Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders.

Wandong Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Handbook of experimental pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Wandong ZhangHuman Health Therapeutics Research Centre, National Research Council of Canada, Ottawa, ON, Canada. Wandong.Zhang@nrc-cnrc.gc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood-brain barrier (BBB) is a special biological property of the brain neurovascular unit (including brain microvessels and capillaries), which facilitates the transport of nutrients into the central nervous system (CNS) and exchanges metabolites but restricts passage of blood-borne neurotoxic substances and drugs/xenobiotics into CNS. BBB plays a crucial role in maintaining the homeostasis and normal physiological functions of CNS but severely impedes the delivery of drugs and biotherapeutics into CNS for treatment of neurological disorders. A variety of technologies have been developed in the past decade for brain drug delivery. Most of these technologies are still in preclinical stage and some are undergoing clinical studies. Only a few have been approved by regulatory agencies for clinical applications. This chapter will overview the strategies and technologies/approaches for brain drug delivery and discuss some of the recent advances in the field.

Indexed as

Blood-Brain BarrierBrainBiological TransportCentral Nervous SystemDrug Delivery SystemsHumansPharmaceutical PreparationsPharmaceutical PreparationsABC transportersAdsorptive-mediated transcytosisAI-assisted drug developmentBlood-brain barrier (BBB)Brain drug deliveryCarrier-mediated transcytosis (CMT)Cell-/BBB-penetrating peptidesCell-mediated drug deliveryFocused ultrasoundIntranasal drug deliveryNanoparticlesNeurovascular unitReceptor-mediated transcytosis (RMT)Viral vector and gene delivery

Identifiers

PMID37528323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.